The new medical world behind “fertility-friendly”
2025-03-24
The new medical world behind "fertility-
New opportunities for the medical industry under the population strategy are becoming increasingly clear.
When “fertility subsidy” became a hot word at the two sessions, the assisted reproductive sector represented by Jinxin Reproductive surged in response, presenting a violent aesthetic of a 40% surge in a single day.
At the just-concluded Two Sessions, Premier Li Qiang pointed out in his “Government Work Report” that a policy to promote fertility will be formulated, childcare subsidies will be issued, integrated childcare services will be vigorously developed, and the supply of universal childcare services will be increased.
This is the latest statement on fertility subsidies at the national level, and it also indirectly confirms that since October last year, when the State Council issued the “Several Measures on Accelerating the Improvement of the Birth Support Policy System and Promoting the Construction of a Birth-Friendly Society” and launched a series of initiatives, the country is accelerating the construction of the “fertility-friendly” systematic project .
During the Two Sessions, many experts also focused on the issue of cervical cancer prevention and control, calling for encouragement and support for the research and development and application of innovative technologies, accelerating the implementation of non-invasive treatment plans for cervical precancerous lesions, and helping to build a fertility-friendly society.
APL-1702, the world’s first photodynamic drug-device combination product for the non-invasive treatment of cervical precancerous lesions that has been clinically validated in an international Phase III clinical trial, developed by Asieris Pharmaceuticals , is expected to meet this clinical need . Currently, APL-1702 is in the application stage for listing, and the National Medical Products Administration’s Drug Evaluation Center has completed the first round of technical review.
APL-1702 is based on the principle of photodynamic therapy. It induces apoptosis of diseased cells and eliminates HPV virus by applying photosensitizers topically and activating light sources of specific wavelengths. Data from Phase III clinical trials show:
Significant efficacy : The response rate (histologically normal or downgraded high-grade lesions and HPV negative conversion) in the treatment group reached 41.1%, almost twice that of the control group (21.7%);
Virus clearance advantage : The clearance rate of high-risk HPV16/18 increased by 103.9% (31.4% VS 15.4%);
Long-lasting effect : In the extended population, the response rate remained high (44%) after 12 months, with some reaching the response criteria at 6 months;
Outstanding safety : only mild adverse reactions, no toxic side effects above grade 3.
Such clinical data demonstrates its potential in preventing cervical cancer. More importantly, APL-1702 can reverse the disease process while preserving an intact cervix, and can protect women’s fertility while preventing and controlling cervical cancer .
In other words, this innovation is not only a response to clinical needs, but also deeply aligned with the national population strategy.
When “curing diseases” and “preserving fertility” can be achieved at the same time, the value of medical technology represented by APL-1702 has gone beyond clinical practice and become the cornerstone of a fertility-friendly society.
https://www.phirda.com/artilce_38272.html?module=trackingCodeGenerator
